Hims Hers Health (NYSE: HIMS) posted a fourth-quarter EPS of $0.11, $0.06 lower than the market expectation of $0.17. Revenue for the quarter was $481.1 million, compared to a consensus expectation of $469.33 million. Hims Hers Health expects Q1 2025 sales of $ 520.00M-$540.00M, compared to the analyst average of $482.50M. Hims Hers Health expects FY 2025 sales of $2.30B-$2.40B, compared to the analyst average of $2.09B.
Hims Hers Health’s shares ended at $51.34.It has increased by 69.22% over the previous three months and 439.29% over the last year. In the previous 90 days, Hims Hers Health has had five positive EPS adjustments and zero negative EPS revisions. See how Hims Hers Health’s stock price has reacted to earnings in the past. According to InvestingPro, Hers Health’s Financial Health score is “great performance”. Check out Hims Hers Health’s latest profits and financials here. Keep track of all forthcoming earnings releases by checking Investing.com’s earnings calendar.
Should you invest $2,000 in HIMS now?
With HIMS generating headlines, shrewd investors wonder: Is it genuinely valued relatively? Determining actual value may be difficult in a market full of pricey darlings. InvestingPro’s powerful AI algorithms researched HIMS alongside hundreds of other stocks to find hidden gems. These inexpensive companies, including HIMS, might provide significant profits once the market corrects. In 2024 alone, our AI detected numerous inexpensive equities, eventually increasing by 30 percent or more. Is HIMS on track for comparable growth? Don’t pass up the opportunity to discover out.
